HK1093523A1 - Lentiviral vectors for the preparation of immunotherapeutical compositions - Google Patents

Lentiviral vectors for the preparation of immunotherapeutical compositions

Info

Publication number: HK1093523A1
Authority: HK; Hong Kong
Prior art keywords: retroviral; response; vector; preparation; cis
Prior art date: 1999-10-11

Application number

HK06111332.8A

Other languages

English (en)

Inventor

Pierre Charneau

Hueseyin Firat

Veronique Zennou

Original Assignee

Pasteur Institut

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-11

Filing date

2003-01-17

Publication date

2007-03-02

2003-01-17 Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut

2007-03-02 Publication of HK1093523A1 publication Critical patent/HK1093523A1/xx

Links

239000013598 vector Substances 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 3
108700019146 Transgenes Proteins 0.000 abstract 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
230000001177 retroviral effect Effects 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
230000000977 initiatory effect Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

HK06111332.8A 1999-10-11 2003-01-17 Lentiviral vectors for the preparation of immunotherapeutical compositions HK1093523A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99402492A EP1092779B1 (en)	1999-10-11	1999-10-11	Lentiviral vectors for the preparation of immunotherapeutical compositions
HK03100475.1A HK1049861B (zh)	1999-10-11	2003-01-17	製備免疫治療組合物的慢病毒載體

Publications (1)

Publication Number	Publication Date
HK1093523A1 true HK1093523A1 (en)	2007-03-02

Family

ID=8242139

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK06111332.8A HK1093523A1 (en)	1999-10-11	2003-01-17	Lentiviral vectors for the preparation of immunotherapeutical compositions
HK03100475.1A HK1049861B (zh)	1999-10-11	2003-01-17	製備免疫治療組合物的慢病毒載體

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK03100475.1A HK1049861B (zh)	1999-10-11	2003-01-17	製備免疫治療組合物的慢病毒載體

Country Status (15)

Country	Link
US (3)	US7968332B2 (xx)
EP (4)	EP1092779B1 (xx)
JP (2)	JP4663943B2 (xx)
CN (2)	CN1840204B (xx)
AT (3)	ATE449858T1 (xx)
AU (3)	AU785060B2 (xx)
CA (1)	CA2387182C (xx)
CY (4)	CY1105149T1 (xx)
DE (3)	DE69941703D1 (xx)
DK (4)	DK1092779T3 (xx)
ES (4)	ES2447115T3 (xx)
HK (2)	HK1093523A1 (xx)
IL (2)	IL148901A0 (xx)
PT (4)	PT1092779E (xx)
WO (1)	WO2001027300A1 (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2777909B1 (fr)	1998-04-24	2002-08-02	Pasteur Institut	Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ES2447115T3 (es)	1999-10-11	2014-03-11	Institut Pasteur	Vectores para la preparación de composiciones inmunoterapéuticas
DE60033045T2 (de) *	1999-10-12	2007-11-08	Institut Pasteur	Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
US7575924B2 (en)	2000-11-13	2009-08-18	Research Development Foundation	Methods and compositions relating to improved lentiviral vectors and their applications
AU2002327412A1 (en)	2001-08-02	2003-02-17	Institut Clayton De La Recherche	Methods and compositions relating to improved lentiviral vector production systems
NZ532060A (en)	2001-10-02	2005-11-25	Inst Clayton De La Rech	Methods and compositions relating to restricted expression lentiviral vectors and their applications
FR2870126B1 (fr) *	2004-05-17	2009-07-17	Pasteur Institut	Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP1712241A1 (en)	2005-04-15	2006-10-18	Centre National De La Recherche Scientifique (Cnrs)	Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US8222029B2 (en)	2005-05-16	2012-07-17	Institut Pasteur	Lentiviral vector-based vaccine
US8158413B2 (en) *	2005-10-17	2012-04-17	Institut Pasteur	Lentiviral vector-based vaccine
EP1739092A1 (en)	2005-06-28	2007-01-03	I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale	Peptidic antagonists of class III semaphorins/neuropilins complexes
EP1748067A1 (en)	2005-07-29	2007-01-31	Institut Pasteur	Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP1948215B1 (en)	2005-11-14	2012-01-11	Centre National De La Recherche Scientifique (Cnrs)	MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
ES2654303T3 (es)	2007-05-04	2018-02-13	University Health Network	Inmunoterapia de IL-12 contra el cáncer
BRPI0813194B8 (pt) *	2007-08-03	2021-05-25	Centre Nat Rech Scient	kit, partículas de vetor lentiviral, composição de vetores plasmídicos, antígeno derivado de hiv-1 quimérico, proteína de envelope de vsv-g, moléculas de ácido nucleico, composição imunogênica e uso de um vetor lentiviral
EP2385107B1 (en)	2010-05-03	2016-08-24	Institut Pasteur	Lentiviral vector based immunological compounds against malaria
EP2666477A1 (en)	2012-05-23	2013-11-27	Theravectys	Lentiviral vectors containing an MHC class I promoter
CN105821078A (zh)	2010-12-09	2016-08-03	巴斯德研究所	用于获得高产量重组蛋白表达的基于mgmt的方法
CA2857998C (en)	2011-12-09	2021-01-19	Institut Pasteur	Multiplex immuno screening assay
US20150182617A1 (en)	2012-07-25	2015-07-02	Theravectys	Glycoproteins for pseudotyping lentivectors
EP3009144A1 (en)	2014-10-15	2016-04-20	Theravectys	Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2015063706A1 (en)	2013-10-31	2015-05-07	Theravectys	Lentiviral vectors for expression of hiv-1 antigens
US10538785B2 (en)	2013-12-23	2020-01-21	Renaud Vaillant	Lyophilized lentiviral vector particles, compositions and methods
SG11201606148UA (en)	2014-01-27	2016-08-30	Theravectys	Lentiviral vectors for generating immune responses against human t lymphotrophic virus type 1
GB201408255D0 (en) *	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
EP3172228B1 (en)	2014-07-25	2019-02-27	Theravectys	Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
EP3031923A1 (en)	2014-12-11	2016-06-15	Institut Pasteur	Lentiviral vector-based japanese encephalitis immunogenic composition
WO2017134265A1 (en)	2016-02-05	2017-08-10	Institut Pasteur	Use of inhibitors of adam12 as adjuvants in tumor therapies
EP3211003A1 (en)	2016-02-24	2017-08-30	Institut Pasteur	T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
EP3276006A1 (en)	2016-07-27	2018-01-31	Theravectys	Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
EP3357504A1 (en)	2017-02-02	2018-08-08	Institut Pasteur	Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
EP3357506A1 (en)	2017-02-02	2018-08-08	Institut Pasteur	Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
EP3648776A4 (en)	2017-07-06	2021-04-07	The Medical College of Wisconsin, Inc.	NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CHS-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR THE THERAPY OF DISORDERS
EP3697809A1 (en)	2017-10-20	2020-08-26	Institut Curie	Dap10/12 based cars adapted for rush
EP3697811A1 (en)	2017-10-20	2020-08-26	Institut Curie	Hook fusion protein for regulating the cellular trafficking of a target protein
CN108118070A (zh) *	2018-01-15	2018-06-05	南京驯鹿医疗技术有限公司	一种慢病毒制备方法
CN108588028B (zh) *	2018-04-26	2021-11-09	中国人民解放军军事科学院军事医学研究院	一种靶向cdkn2a的cic细胞模型及其制备方法
CA3136252A1 (en)	2019-05-10	2020-11-19	Francesca DI NUNZIO	Live imaging system to visualize the retro-transcribed viral dna genome
WO2021234110A1 (en)	2020-05-20	2021-11-25	Institut Curie	Single domain antibodies and their use in cancer therapies
AU2021308424A1 (en)	2020-07-15	2023-02-09	Institut Pasteur	SARS-CoV-2 immunogenic compositions, vaccines, and methods
WO2022167831A1 (en)	2021-02-02	2022-08-11	Institut Pasteur	Sars-cov-2 immunogenic compositions, vaccines, and methods
CN117120085A (zh)	2020-07-15	2023-11-24	巴斯德研究所	Sars-cov-2免疫原性组合物、疫苗和方法
GB202013940D0 (en)	2020-09-04	2020-10-21	Synpromics Ltd	Regulatory nucleic acid sequences
EP4214223A1 (en)	2020-09-21	2023-07-26	Theravectys	High throughput methods and products for sars-cov-2 sero-neutralization assay
WO2022076556A2 (en)	2020-10-07	2022-04-14	Asklepios Biopharmaceutical, Inc.	Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
EP3984548A1 (en)	2020-10-16	2022-04-20	Institut Pasteur	Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
EP4229090A1 (en)	2020-10-16	2023-08-23	Université d'Aix-Marseille	Anti-gpc4 single domain antibodies
IL304031A (en)	2021-01-14	2023-08-01	Inst Curie	Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
WO2022189656A1 (en)	2021-03-12	2022-09-15	Institut Pasteur	Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
AU2022386715A1 (en)	2021-11-15	2024-05-16	Institut Pasteur	Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024023135A1 (en)	2022-07-27	2024-02-01	Theravectys	Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024084041A2 (en)	2022-10-21	2024-04-25	Institut Pasteur	Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1038306A (zh) *	1988-03-21	1989-12-27	维吉恩公司	重组反转录病毒
GB9213559D0 (en) *	1992-06-25	1992-08-12	Smithkline Beecham Biolog	Vaccines
JPH06261764A (ja)	1993-02-17	1994-09-20	Wisconsin Alumni Res Found	混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
US6001349A (en) *	1995-02-22	1999-12-14	Therion Biologics Corporation	Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6013516A (en) *	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
EP0885302A1 (en) *	1996-03-05	1998-12-23	The Regents Of The University Of California	Recombinant live feline immunodeficiency virus and proviral dna vaccines
JP2001513643A (ja) *	1997-03-06	2001-09-04	ウーベルラ、クラウス	レンチウイルスをベースとするベクター及びベクター系
EP1007716A1 (en)	1997-04-17	2000-06-14	The Regents Of The University Of California	Use of lentiviral vectors for antigen presentation in dendritic cells
US5891432A (en) *	1997-07-29	1999-04-06	The Immune Response Corporation	Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
ES2217585T3 (es) *	1997-10-10	2004-11-01	The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services	Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
KR20010015817A (ko) *	1997-11-14	2001-02-26	유로-셀티큐 에스.에이.	항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체
FR2777909B1 (fr) *	1998-04-24	2002-08-02	Pasteur Institut	Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) *	1998-06-03	2009-11-24	Kappes John C	Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US6555342B1 (en) *	1998-06-03	2003-04-29	Uab Research Foundation	Fusion protein delivery system and uses thereof
GB9825524D0 (en)	1998-11-20	1999-01-13	Oxford Biomedica Ltd	Vector
ES2447115T3 (es)	1999-10-11	2014-03-11	Institut Pasteur	Vectores para la preparación de composiciones inmunoterapéuticas
DE60033045T2 (de)	1999-10-12	2007-11-08	Institut Pasteur	Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
US20030194392A1 (en)	2002-04-10	2003-10-16	Pierre Charneau	Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8158413B2 (en)	2005-10-17	2012-04-17	Institut Pasteur	Lentiviral vector-based vaccine
US8222029B2 (en)	2005-05-16	2012-07-17	Institut Pasteur	Lentiviral vector-based vaccine

1999
- 1999-10-11 ES ES09176531.3T patent/ES2447115T3/es not_active Expired - Lifetime
- 1999-10-11 EP EP99402492A patent/EP1092779B1/en not_active Expired - Lifetime
- 1999-10-11 DK DK99402492.5T patent/DK1092779T3/da active
- 1999-10-11 DK DK09176531.3T patent/DK2169073T3/da active
- 1999-10-11 EP EP09176531.3A patent/EP2169073B1/en not_active Expired - Lifetime
- 1999-10-11 DE DE69941703T patent/DE69941703D1/de not_active Expired - Lifetime
- 1999-10-11 ES ES99402492T patent/ES2337429T3/es not_active Expired - Lifetime
- 1999-10-11 PT PT99402492T patent/PT1092779E/pt unknown
- 1999-10-11 AT AT99402492T patent/ATE449858T1/de active
- 1999-10-11 PT PT91765313T patent/PT2169073E/pt unknown
2000
- 2000-10-10 IL IL14890100A patent/IL148901A0/xx active IP Right Grant
- 2000-10-10 PT PT00972845T patent/PT1222300E/pt unknown
- 2000-10-10 WO PCT/EP2000/010419 patent/WO2001027300A1/en active Application Filing
- 2000-10-10 AU AU11435/01A patent/AU785060B2/en not_active Expired
- 2000-10-10 CN CN2006100045648A patent/CN1840204B/zh not_active Expired - Lifetime
- 2000-10-10 DK DK06001198T patent/DK1650309T3/da active
- 2000-10-10 AT AT06001198T patent/ATE441721T1/de active
- 2000-10-10 PT PT06001198T patent/PT1650309E/pt unknown
- 2000-10-10 JP JP2001530503A patent/JP4663943B2/ja not_active Expired - Lifetime
- 2000-10-10 DE DE60042903T patent/DE60042903D1/de not_active Expired - Lifetime
- 2000-10-10 CN CN008141770A patent/CN1379820B/zh not_active Expired - Lifetime
- 2000-10-10 DE DE60028066T patent/DE60028066T2/de not_active Expired - Lifetime
- 2000-10-10 ES ES06001198T patent/ES2332930T3/es not_active Expired - Lifetime
- 2000-10-10 ES ES00972845T patent/ES2262545T3/es not_active Expired - Lifetime
- 2000-10-10 CA CA2387182A patent/CA2387182C/en not_active Expired - Lifetime
- 2000-10-10 AT AT00972845T patent/ATE326541T1/de active
- 2000-10-10 EP EP00972845A patent/EP1222300B1/en not_active Expired - Lifetime
- 2000-10-10 EP EP06001198A patent/EP1650309B1/en not_active Expired - Lifetime
- 2000-10-10 DK DK00972845T patent/DK1222300T3/da active
2002
- 2002-12-06 US US10/313,038 patent/US7968332B2/en not_active Expired - Fee Related
2003
- 2003-01-17 HK HK06111332.8A patent/HK1093523A1/xx not_active IP Right Cessation
- 2003-01-17 HK HK03100475.1A patent/HK1049861B/zh not_active IP Right Cessation
2006
- 2006-08-10 CY CY20061101129T patent/CY1105149T1/el unknown
- 2006-12-14 AU AU2006252062A patent/AU2006252062B2/en not_active Expired
2009
- 2009-11-24 CY CY20091101210T patent/CY1110551T1/el unknown
2010
- 2010-02-17 CY CY20101100155T patent/CY1110611T1/el unknown
- 2010-03-24 IL IL204703A patent/IL204703A0/en active IP Right Grant
- 2010-07-21 AU AU2010203111A patent/AU2010203111B2/en not_active Expired
- 2010-11-10 JP JP2010251771A patent/JP5265643B2/ja not_active Expired - Lifetime
2011
- 2011-05-10 US US13/104,380 patent/US8349606B2/en not_active Expired - Lifetime
2012
- 2012-12-12 US US13/711,898 patent/US8652807B2/en not_active Expired - Fee Related
2014
- 2014-02-06 CY CY20141100100T patent/CY1114819T1/el unknown

Also Published As

Publication number	Publication date
DE60042903D1 (de)	2009-10-15
US20040081636A1 (en)	2004-04-29
EP1650309B1 (en)	2009-09-02
CN1379820B (zh)	2011-04-13
AU2006252062A1 (en)	2007-01-18
HK1049861A1 (en)	2003-05-30
EP2169073B1 (en)	2013-11-13
US20110250650A1 (en)	2011-10-13
CA2387182A1 (en)	2001-04-19
US20130157357A1 (en)	2013-06-20
DE60028066D1 (de)	2006-06-22
EP1222300B1 (en)	2006-05-17
ES2262545T3 (es)	2006-12-01
CY1105149T1 (el)	2010-03-03
WO2001027300A1 (en)	2001-04-19
US8652807B2 (en)	2014-02-18
CA2387182C (en)	2010-12-21
ES2447115T3 (es)	2014-03-11
HK1049861B (zh)	2006-12-22
CN1379820A (zh)	2002-11-13
US8349606B2 (en)	2013-01-08
DE60028066T2 (de)	2007-01-18
CY1110551T1 (el)	2015-04-29
AU2010203111B2 (en)	2012-01-19
EP1092779B1 (en)	2009-11-25
JP2003511080A (ja)	2003-03-25
DK1222300T3 (da)	2006-09-18
PT1222300E (pt)	2006-09-29
PT1092779E (pt)	2010-01-19
CY1114819T1 (el)	2016-12-14
DK1092779T3 (da)	2010-02-15
PT2169073E (pt)	2014-02-20
ATE326541T1 (de)	2006-06-15
DE69941703D1 (de)	2010-01-07
AU785060B2 (en)	2006-09-14
ATE449858T1 (de)	2009-12-15
ATE441721T1 (de)	2009-09-15
CN1840204A (zh)	2006-10-04
PT1650309E (pt)	2009-11-18
AU2006252062B2 (en)	2010-04-22
EP1650309A1 (en)	2006-04-26
DK2169073T3 (da)	2014-02-10
DK1650309T3 (da)	2009-11-30
ES2337429T3 (es)	2010-04-23
EP2169073A1 (en)	2010-03-31
AU2010203111A1 (en)	2010-08-12
CY1110611T1 (el)	2015-04-29
US7968332B2 (en)	2011-06-28
AU1143501A (en)	2001-04-23
JP5265643B2 (ja)	2013-08-14
JP4663943B2 (ja)	2011-04-06
CN1840204B (zh)	2011-09-07
EP1092779A1 (en)	2001-04-18
EP1222300A1 (en)	2002-07-17
JP2011078420A (ja)	2011-04-21
IL148901A0 (en)	2002-09-12
ES2332930T3 (es)	2010-02-15
IL204703A0 (en)	2010-11-30

Legal Events

Date	Code	Title	Description
2020-10-16	PE	Patent expired	Effective date: 20201009

Publication	Publication Date	Title
HK1093523A1 (en)	2007-03-02	Lentiviral vectors for the preparation of immunotherapeutical compositions
EP0878545A3 (en)	1998-12-16	OSP a protein of borrelia burgdorferi subgroups, encoding genes and vaccines
EP1084261B8 (en)	2004-12-15	Recombinant venezuelan equine encephalitis virus vaccine
EP0837928A4 (en)	2003-01-22	COMPOSITIONS OF RECOMBINED POXVIRUS-CYTOMEGALOVIRUS AND THEIR USE
GEP20032902B (en)	2003-02-25	Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV
BG103334A (en)	2000-06-30	Antiviral vectors
NZ334811A (en)	2000-09-29	Strain selection of pneumococcal surface proteins
EP1409694A4 (en)	2006-02-08	POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
WO2000012535A3 (en)	2000-06-08	Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
EP0775746A3 (en)	1997-06-11	Coccidiosis poultry vaccine
PT831899E (pt)	2008-11-13	Composições de poxvírus-calicivírus recombinantes e suas utilizações
EP0801575A4 (en)	2001-08-16	RETROVIRAL VECTORS FOR EXPRESSION IN EMBRYONIC CELLS
EP0832266A4 (en)	2000-06-28	ORAL ADMINISTRATION OF VECTORS OF VENUS ASSOCIATED WITH ADENOVIRUS
EP1840209A3 (en)	2008-03-05	Adeno-associated virus vectors and use thereof
WO1999002724A3 (en)	1999-04-01	Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods
FR2829498B1 (fr)	2003-11-28	Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2005027844A3 (en)	2005-10-06	Dna vaccine compositions and methods of use
WO2003029285A3 (en)	2004-01-22	Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2007143606A3 (en)	2008-11-13	Hiv-1 clade a consensus sequences, antigens, and transgenes
WO1999014333A3 (en)	1999-06-03	Improved method of production of pneumococcal surface proteins
ES2008391A6 (es)	1989-07-16	Un metodo para producir isopenicilina n sintetasa.
SE9503379D0 (sv)	1995-09-29	A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
WO2004003010A3 (en)	2004-02-26	Nuclear hormone receptor ligano-binding domain containing protein
Wood	1993	Private Groups Face Off in Brazilian Petrochemical Battle
Church et al.	1991	Fractured hopes.